Clinical trials: Core Binding Factor Acute Myeloid Leukemia
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid…
- Conditions
- Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome
- Trial name
- NCT00801489
- Testing
- Cytarabine, Decitabine, Filgrastim-sndz
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
This study will examine the appropriate dose and side effects of dasatinib, when it is given with the standard of care chemotherapy for children and adolescents with Acute Myeloid Leukemia (AML).
- Trial name
- NCT02680951
- Testing
- Dasatinib, Fludarabine, Cytarabine
- Sponsor
- Emory University
Leukemia, Myeloid
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia
Primary study objective is the evaluation of efficacy of autologous hematopoietic cell transplantation (HCT) with core-binding factor (CBF) positive acute myeloid leukemia (AML) in the first CR (CR1) in terms of relapse incidence…
- Trial name
- NCT01050036
- Testing
- autologous hematopoietic cell transplantation
- Where
- 11 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Asan Medical Center
Acute Myeloid Leukemia (AML)
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)
This is a randomized phase III open-label, multicenter trial evaluating standard induction therapy (daunorubicin [DNR] and cytarabine [Ara-C]) and consolidation therapy (high-dose cytarabine [HDAC]) with or without dasatinib in…
- Trial name
- NCT02013648
- Testing
- Dasatinib, Cytarabine, Daunorubicin
- Where
- 54 sites in Austria, Germany
- Volunteers
- 204 people
- Sponsor
- University of Ulm
Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia
The purpose of this single-arm, open label, phase-II trial, is to determine whether the association of Midostaurin to standard induction, consolidation therapy and in maintenance therapy as single agent, is effective in decrease…
- Trial name
- AML FLT3 (NCT03686345)
- Testing
- Midostaurin
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- Niguarda Hospital
Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors
Avapritinib in CBF-AML With KIT Mutations
AML with t(8; 21)(q22; q22) or inv(16)(p13; q22)/t(16; 16)(p13; q22) is known as CBF-AML. KIT mutations are common in CBF-AML, which have a worse prognosis.This study is aimed to evaluate the efficacy of Avapritinib, an highly…
- Trial name
- NCT05821738
- Testing
- Avapritinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia (AML)
Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
This is a Phase Ib/IIa open-labeled multi-center trial evaluating the feasibility of dasatinib given after standard induction therapy with daunorubicin (DNR) and cytarabine (ARA-C), after consolidation therapy with high-dose…
- Trial name
- NCT00850382
- Testing
- Dasatinib, daunorubicin, Cytarabine
- Where
- 50 sites in Austria, Germany
- Volunteers
- 89 people
- Sponsor
- University of Ulm
Core Binding Factor Acute Myeloid Leukemia
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML
Core-binding factor acute myeloid leukemia accounts for 10-15% of AML and is categorized as favorable-risk AML. However, the 5-year CIR was up to 40% in this group of patients.
- Trial name
- NCT05404516
- Testing
- Sorafenib, Idarubicin, Cytarabine
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Myeloid Leukemia
Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia
Core binding factor (CBF) positive acute myeloid leukemia (AML) consist of 15% of patients in overall AML, expected to harbor a favorable prognosis. However, around a half of cases relapses.
- Trial name
- NCT01066286
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
AML, Childhood, Relapse/Recurrence
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
The purpose of this study is to evaluate the efficacy and safety of avapritinib in relapsed or refractory pediatric core binding factor acute myeloid leukemia with KIT mutation.
- Conditions
- AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia
- Trial name
- NCT06316960
- Testing
- Avapritinib, Azacitidine Injection, Decitabine Injection
- Where
- 12 sites in China
- Volunteers
- 50 people
- Sponsor
- Children's Hospital of Soochow University
Acute Myeloblastic Leukemia Core Binding Factor
Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor
Acute Core Binding Factor leukemias represent a specific category of acute myeloid leukemias that share prognostic factors, a specific mutational profile, and a favorable response to chemotherapy.
- Trial name
- RETRO-CBF (NCT05070208)
- Testing
- NOT PROVIDED
- Where
- 26 sites in France
- Volunteers
- 400 people
- Sponsor
- Acute Leukemia French Association
Core Binding Factor Acute Myeloid Leukemia
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
This phase II MYELOMATCH treatment trial compares the effect of venetoclax to gemtuzumab ozogamicin, when given with cytarabine and daunorubicin ("7+3" regimen), for the treatment of patients with core binding factor acute…
- Trial name
- NCT06917911
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Cytarabine
- Where
- 74 sites in United States, Puerto Rico
- Volunteers
- 162 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Core-Binding Factor
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
The purpose of the study is to determine whether Fludarabine in combination with cytarabine is more effective than high-dose cytarabine in post-remission therapy for patients with core-binding factor acute myeloid leukemia
- Trial name
- NCT02926586
- Testing
- Fludarabine, Cytarabine
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
This phase II trial studies the side effects and how well giving combination chemotherapy together with dasatinib works in treating patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Trial name
- NCT01238211
- Testing
- Cytarabine, Dasatinib, Daunorubicin Hydrochloride
- Where
- 65 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Timed-Sequential Induction in CBF-AML
Core binding factor (CBF) acute myeloid leukemias (AML) include AMLs carrying the t(8;21) translocation as well as AMLs carrying either the inversion of chromosome 16 or translocation t(16;16).
- Trial name
- NCT00428558
- Testing
- Chemotherapy (DAUNORUBICINE-CYTARABINE)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Myelogenous Leukemia
Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia
In patients with Core Binding Factors Acute Myelogenous Leukemia, the level of Minimal Residual Disease after chemotherapy is predictive of relapse.
- Trial name
- DasaCBF (NCT02113319)
- Testing
- dasatinib
- Where
- France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Angers
Acute Myeloid Leukemia
Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)
Evaluation of efficacy of autologous hematopoietic cell transplantation (HCT) with core-binding factor (CBF) positive acute myeloid leukemia (AML) in the first CR (CR1).
- Trial name
- CBF(+)AML (NCT01146977)
- Testing
- HDAC chemotherapy, Autologous HCT
- Where
- South Korea
- Volunteers
- 43 people
- Sponsor
- Cooperative Study Group A for Hematology
Acute Myeloid Leukemia
The Efficacy of Allo-HSCT in ND HR-CBF-AML
For newly diagnosed high-relapse-risk core-binding-factor acute myeloid leukemia participants, the investigators aim to perform allogeneic hematopoietic stem cell transplantation after participants finished one cycle of induction…
- Trial name
- NCT06458244
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Chemotherapy
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Ruijin Hospital